Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) traded with an addition of $1.15 to $21.80 on Thursday, an upside of 5.57 percent. An average of 2,231,040 shares of common stock have been traded in the last five days. There was a gain of $0.79 in the past week, and it reached a new high 8 times over the past 12 months. The last 20 days have seen an average of 2,975,690 shares traded, while the 50-day average volume stands at 3,706,670.
AUPH stock has decreased by -8.79% in the last month. The company shares reached their 1-month lowest point of $17.65 on 10/06/21. With the stock rallying to its 52-week high on 09/21/21, shares of the company touched a low of $9.72 and a high of $24.18 in 52 weeks. It has reached a new high 10 times so far this year and achieved 49.31% or $8.00 in price. In spite of this, the price is down -9.84% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
30 days have passed since Aurinia Pharmaceuticals Inc. (AUPH) last reported insider trading activity. Huizinga Robert Bindert, who is EVP of Research, most recently acquired $32,500 shares at $23.99 per share on Sep 21. In this transaction, the insider spent $779,533. Chief Business Officer, Martin Michael Robert, disposed of 87,500 shares at a price of $24.02 on Sep 21. The insider now owns more than $2,101,750 worth of shares. Prior to that, Chief Business Officer Martin Michael Robert went on to Sale 28,500 shares at $21.65 each on Sep 20. An amount of $616,975 was transacted.
Aurinia Pharmaceuticals Inc. (AUPH) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 33.21 for the sector. The stock’s beta is 0.34. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 46.99, the price-to-book (PB) ratio at 7.97.
The quick ratio of Aurinia Pharmaceuticals Inc. for the three months ended June 29 was 11.30, and the current ratio was 11.90, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Aurinia Pharmaceuticals Inc.’s EBITDA margin for the year ending June 29 is -191.77%. Its gross profit as reported stood at $147.6 million compared to revenue of $50.12 million.
In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$47.01 million in the quarter, while revenues were grew 100.0%. The analyst consensus anticipated Aurinia Pharmaceuticals Inc.’s latest quarter earnings to come in at -$0.36 per share, but it turned out to be -$0.37, a -2.80% surprise. For the quarter, EBITDA amounted to -$47.4 million. Shareholders own equity worth $128.4 million.
From a technical analysis perspective, let’s take a brief look at Aurinia Pharmaceuticals Inc. (AUPH) price momentum. RSI 9-day as of the close on 20 October was 59.63%, suggesting the stock is Neutral, with historical volatility in this time frame at 50.30%.
As of today, AUPH’s price is $20.54 +3.75% or $0.79 from its 5-day moving average. AUPH is currently trading -7.15% lower than its 20-day SMA and +54.38% higher than its 100-day SMA. However, the stock’s current price level is +44.86% above the SMA50 and +66.77% above the SMA200.
The stochastic %K and %D were 61.76% and 48.95%, respectively, and the average true range (ATR) was 1.31. With the 14-day stochastic at 83.82% and the average true range at 1.37, the RSI (14) stands at 57.52%. The stock has reached 0.12 on the 9-day MACD Oscillator while the 14-day reading was at 0.34.
H.C. Wainwright reiterated its a Buy rating on Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), but raised their price target to $30, indicating a potential price increase of 27.33% for the stock. The consensus rating for Aurinia Pharmaceuticals Inc. (AUPH) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell AUPH, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 7 others rate it as a “buy”.
What is AUPH’s price target for the next 12 months?
Analysts predict a range of price targets between $23.00 and $35.00, with a median target of $31.00. Taking a look at these predictions, the average price target given by analysts for Aurinia Pharmaceuticals Inc. (AUPH) stock is $30.00.